Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update

Go back to Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) Delayed: 30.11 +1.12 (3.86%)
Previous Close $28.99    52 Week High $5.17 
Open $29.57    52 Week Low $0.94 
Day High $30.70    P/E N/A 
Day Low $28.41    EPS $0.00 
Volume 5,083,018